Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial

Paul Y. Kwo, Eric J. Lawitz, Jonathan McCone, Eugene R. Schiff, John M. Vierling, David Pound, Mitchell N. Davis, Joseph S. Galati, Stuart C. Gordon, Natarajan Ravendhran, Lorenzo Rossaro, Frank H. Anderson, Ira M. Jacobson, Raymond Rubin, Kenneth Koury, Lisa D. Pedicone, Clifford A. Brass, Eirum Chaudhri, Janice K. Albrecht

Research output: Contribution to journalArticlepeer-review

609 Scopus citations

Fingerprint Dive into the research topics of 'Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences